November 04, 2024
Developing treatments for people with mental health conditions
October 14, 2024
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare
October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
October 08, 2024
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
September 27, 2024
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
September 25, 2024
Boehringer Ingelheim expands cancer research at its Vienna site
September 16, 2024
Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 09, 2024
Zongertinib shows encouraging efficacy and tolerability profile in lung cancer patients
September 05, 2024
Geographic Atrophy treatment to move to Phase II
September 03, 2024
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
August 30, 2024
Boehringer Ingelheim announces appointments Board of Managing Directors
August 27, 2024
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC
July 29, 2024
Boehringer Ingelheim acquires Nerio Therapeutics
July 29, 2024
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 08, 2024
Boehringer Ingelheim produces its own green energy
July 03, 2024
Boehringer Ingelheim advances SIRPα immuno-oncology program
July 01, 2024
Phase 1 start for novel triple agonist obesity treatment
June 07, 2024
Survodutide shows breakthrough improvement in liver fibrosis
May 28, 2024
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
May 13, 2024
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3)
May 06, 2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
April 25, 2024
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 09, 2024
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
April 06, 2024
Results announced from EMPACT-MI phase III trial
March 19, 2024
SPEVIGO® approved for expanded indications in China and the US
March 11, 2024
New partnership to develop schizophrenia treatments
February 26, 2024
Survodutide Phase II trial shows groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 19, 2024
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
January 18, 2024
Global Top Employer 2024 certification reflects Boehringer Ingelheim’s impactful people development
January 11, 2024
Boehringer expands production site in Greece for new medicine
January 10, 2024
SENVELGO® wins Best New Product for Companion Animals award
January 09, 2024
Kicking off 2024 with five new R&D partnerships
Media Contacts
Head of Global Media Relations
E-Mail:
harro.ten_wolde@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-181352
Senior Media Relations Manager
E-Mail:
tereza.urbankova@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-184817
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Animal Health Communications
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799